Acute toxicity comparison of magnetic resonance‐guided adaptive versus fiducial or computed tomography‐guided non‐adaptive prostate stereotactic body radiotherapy: A systematic review and meta‐analysis

Magnetic resonance imaging-guided daily adaptive prostate stereotactic radiation (MRg-A-SBRT) is a treatment that may allow for delivery of prostate radiation more precisely than other radiotherapy techniques . But it is unknown whether this reduces side effects compared to standardly used computed tomography guided prostate cancer treatment . The pooled estimates for acute grade 2 or… Continue reading Acute toxicity comparison of magnetic resonance‐guided adaptive versus fiducial or computed tomography‐guided non‐adaptive prostate stereotactic body radiotherapy: A systematic review and meta‐analysis

Acute toxicity comparison of magnetic resonance‐guided adaptive versus fiducial or computed tomography‐guided non‐adaptive prostate stereotactic body radiotherapy: A systematic review and meta‐analysis

Magnetic resonance imaging-guided daily adaptive prostate stereotactic radiation (MRg-A-SBRT) is a treatment that may allow for delivery of prostate radiation more precisely than other radiotherapy techniques . But it is unknown whether this reduces side effects compared to standardly used computed tomography guided prostate cancer treatment . The pooled estimates for acute grade 2 or… Continue reading Acute toxicity comparison of magnetic resonance‐guided adaptive versus fiducial or computed tomography‐guided non‐adaptive prostate stereotactic body radiotherapy: A systematic review and meta‐analysis

Experience with the US health care system for Black and White patients with advanced prostate cancer

A prospective cohort study of 701 participants (20% identifying as Black) enrolled in the International Registry for Men with Advanced Prostate Cancer at 37 US sites from 2017 to 2022 . Participants were asked six questions from the Cancer Australia National Cancer Control Indicators about their experience with care at study enrollment . Black participants… Continue reading Experience with the US health care system for Black and White patients with advanced prostate cancer

Experience with the US health care system for Black and White patients with advanced prostate cancer

A prospective cohort study of 701 participants (20% identifying as Black) enrolled in the International Registry for Men with Advanced Prostate Cancer at 37 US sites from 2017 to 2022 . Participants were asked six questions from the Cancer Australia National Cancer Control Indicators about their experience with care at study enrollment . Black participants… Continue reading Experience with the US health care system for Black and White patients with advanced prostate cancer